Combination therapy led to complete remission in more than 50% of mice with different tumor types, many of which were resistant to ICB therapy alone.

In this Point of View column,, CEO of Taconic Biosciences, explores redefining preclinical models for the future of drug development.

To model tumor biology, Emulate’s platform introduces stromal contents by tuning the extracellular matrix stiffness and composition, as well as recreating essential gradients. The method captures ...

From a chemistry, manufacturing, and controls (CMC) perspective, ADCs present unique hurdles. “ADCs introduce unique challenges across areas like process and purification development, analytical ...

The data shows when the protein is removed from neurons or has its signaling activity blocked with drugs, axonal fibers grew more effectively.

The growing emphasis on CLD is evident in market projections. The global cell line development market is expected to expand ...

Once physical security measures are circumvented, there are no measures in place to protect cells from theft, abuse, or unauthorized use.

From payload optimization to integrated GMP manufacturing, companies aim to elevate oncology ADCs to standard of care.

Findings may support development of more refined personalized breast cancer risk prediction models for BRCA1 pathogenic ...

ALS is a heterogeneous disease. While 10-15% of cases are linked to inherited mutations, nearly 85% are sporadic.

Overcoming efficacy, safety, and manufacturing hurdles through innovative personalized cancer vaccine design ...

Edison is the commercial spinout of FutureHouse, an AI scientist non-profit backed by former Google CEO Eric Schmidt and co-founded by Sam Rodriques, PhD, former group leader at the Francis Crick ...